SEI Investments’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15M | Buy |
75,188
+28,820
| +62% | +$5.7M | 0.01% | 920 |
|
|
2025
Q4 | $8.77M | Buy |
46,368
+18,944
| +69% | +$3.64M | 0.01% | 1118 |
|
|
2025
Q3 | $4.86M | Buy |
27,424
+6,012
| +28% | +$894K | 0.01% | 1305 |
|
|
2025
Q2 | $2.43M | Buy |
21,412
+1,035
| +5% | +$111K | ﹤0.01% | 1573 |
|
|
2025
Q1 | $2.14M | Sell |
20,377
-7,105
| -26% | -$803K | ﹤0.01% | 1609 |
|
|
2024
Q4 | $2.94M | Buy |
27,482
+677
| +3% | +$76.5K | ﹤0.01% | 1522 |
|
|
2024
Q3 | $2.68M | Sell |
26,805
-21,260
| -44% | -$2.14M | ﹤0.01% | 1549 |
|
|
2024
Q2 | $4.05M | Buy |
48,065
+12,224
| +34% | +$973K | 0.01% | 1314 |
|
|
2024
Q1 | $2.62M | Buy |
35,841
+24,784
| +224% | +$1.83M | ﹤0.01% | 1500 |
|
|
2023
Q4 | $790K | Buy |
11,057
+3,619
| +49% | +$214K | ﹤0.01% | 1950 |
|
|
2023
Q3 | $446K | Buy |
7,438
+230
| +3% | +$15.1K | ﹤0.01% | 2148 |
|
|
2023
Q2 | $520K | Buy |
7,208
+1,758
| +32% | +$132K | ﹤0.01% | 2121 |
|
|
2023
Q1 | $401K | Buy |
5,450
+603
| +12% | +$42.9K | ﹤0.01% | 2219 |
|
|
2022
Q4 | $324K | Sell |
4,847
-3,014
| -38% | -$196K | ﹤0.01% | 2168 |
|
|
2022
Q3 | $422K | Buy |
7,861
+3,400
| +76% | +$200K | ﹤0.01% | 2169 |
|
|
2022
Q2 | $251K | Buy |
4,461
+268
| +6% | +$15.2K | ﹤0.01% | 2399 |
|
|
2022
Q1 | $296K | Sell |
4,193
-17,055
| -80% | -$1.24M | ﹤0.01% | 2313 |
|
|
2021
Q4 | $2.04M | Sell |
21,248
-3,259
| -13% | -$301K | ﹤0.01% | 1580 |
|
|
2021
Q3 | $2.13M | Buy |
24,507
+16,657
| +212% | +$1.29M | ﹤0.01% | 1479 |
|
|
2021
Q2 | $640K | Sell |
7,850
-2,204
| -22% | -$183K | ﹤0.01% | 1977 |
|
|
2021
Q1 | $863K | Sell |
10,054
-83,629
| -89% | -$7.91M | ﹤0.01% | 1814 |
|
|
2020
Q4 | $5.81M | Sell |
93,683
-1,074
| -1% | -$61.2K | 0.02% | 909 |
|
|
2020
Q3 | $5.63M | Buy |
94,757
+20,553
| +28% | +$1.4M | 0.02% | 815 |
|
|
2020
Q2 | $5.17M | Buy |
74,204
+13,102
| +21% | +$831K | 0.02% | 846 |
|
|
2020
Q1 | $2.76M | Buy |
61,102
+21,237
| +53% | +$1.2M | 0.01% | 1014 |
|
|
2019
Q4 | $2.65M | Sell |
39,865
-86,214
| -68% | -$5.76M | 0.01% | 1205 |
|
|
2019
Q3 | $7.87M | Buy |
126,079
+85,783
| +213% | +$5.39M | 0.02% | 706 |
|
|
2019
Q2 | $2.9M | Buy |
40,296
+6,117
| +18% | +$451K | 0.01% | 1161 |
|
|
2019
Q1 | $2.72M | Sell |
34,179
-10,582
| -24% | -$802K | 0.01% | 1184 |
|
|
2018
Q4 | $6.24M | Buy |
44,761
+14,746
| +49% | +$1.57M | 0.02% | 773 |
|
|
2018
Q3 | $5.13M | Sell |
30,015
-10,158
| -25% | -$1.53M | 0.02% | 856 |
|
|
2018
Q2 | $5.19M | Buy |
40,173
+18,266
| +83% | +$2.04M | 0.02% | 905 |
|
|
2018
Q1 | $2.26M | Buy |
21,907
+4,503
| +26% | +$445K | 0.01% | 1166 |
|
|
2017
Q4 | $1.49M | Buy |
17,404
+867
| +5% | +$75.1K | 0.01% | 1399 |
|
|
2017
Q3 | $1.41M | Sell |
16,537
-24,610
| -60% | -$1.95M | 0.01% | 1348 |
|
|
2017
Q2 | $3.12M | Buy |
41,147
+36,870
| +862% | +$2.58M | 0.01% | 1029 |
|
|
2017
Q1 | $282K | Sell |
4,277
-17,012
| -80% | -$1.12M | ﹤0.01% | 1710 |
|
|
2016
Q4 | $1.35M | Buy |
21,289
+7,369
| +53% | +$465K | 0.01% | 1279 |
|
|
2016
Q3 | $886K | Sell |
13,920
-1,496
| -10% | -$110K | ﹤0.01% | 1286 |
|
|
2016
Q2 | $1.15M | Sell |
15,416
-1,246
| -7% | -$92.5K | 0.01% | 1140 |
|
|
2016
Q1 | $1.11M | Sell |
16,662
-29,129
| -64% | -$1.77M | 0.01% | 1125 |
|
|
2015
Q4 | $3.1M | Buy |
45,791
+17,697
| +63% | +$1.09M | 0.02% | 831 |
|
|
2015
Q3 | $1.5M | Buy |
28,094
+11,423
| +69% | +$693K | 0.01% | 905 |
|
|
2015
Q2 | $1.05M | Buy |
16,671
+6,109
| +58% | +$333K | 0.01% | 963 |
|
|
2015
Q1 | $506K | Buy |
+10,562
| New | +$405K | ﹤0.01% | 1177 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
SEI Investments's LGND Position: Q1 2026 in Review
SEI Investments increased its Ligand Pharmaceuticals (LGND) stake by 62% in Q1 2026, buying an estimated $5.7M and bringing the position to 75,188 shares worth $15M. The position accounts for 0.01% of the portfolio, ranked #920.
SEI Investments first reported a position in LGND in Q1 2015 and has held it in 45 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- SEI Investments held 75,188 shares of Ligand Pharmaceuticals worth $15M as of Q1 2026.
- SEI Investments bought 28,820 Ligand Pharmaceuticals shares in Q1 2026, an estimated $5.7M.
- Ligand Pharmaceuticals made up 0.01% of SEI Investments's portfolio in Q1 2026, its #920 holding.
- SEI Investments first reported a position in Ligand Pharmaceuticals in Q1 2015 and has held it in 45 quarters since.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.